According to the Nature Conservancy, some 10 million live Christmas trees end up in landfills every year. There are options ...

One example of a game you can play with a group—both big and small—is "Would You Rather." And while general questions can still be perfectly entertaining, we think these Christmas "Would You Rather" ...

(Laughter) True. Some people feel strongly enough about bugs and dirt and dust to wash their Christmas trees before dragging them through the door. Businesswoman and gardener Carmen Johnston washed ...

John Savarino teaches ciLiving host, Jaclyn Friedlander about money related questions from the money tree. In this video, we answer money-related questions from the Money Tree, sparking meaningful ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...